Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

Andreas Hochhaus, D.W. Kim, P. Rousselot, P.E. Dorlhiac-Llacer, J. Milone, S. Francis, E. Bleickardt, H. Kantarjian

Blood (2006) 108 (11): 166.

https://doi.org/10.1182/blood.V108.11.166.166

Published: 2006

Journal Articles

First Results from a Collaborative Initiative To Develop an International Scale for the Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors.

Susan Branford, Nicholas C.P. Cross, Andreas Hochhaus, Jerald Radich, Giuseppe Saglio, D.W. Kim, Linda Fletcher, Y.L. Wang, Melinda Higgins, Serge Kovalenko, Lee-Yung Shih, J.L. Tang, Edmond Ma, Michael Wong, Jorge Cortes, Dan Jones, Kevin Lynch, John M. Goldman, Timothy Hughes

Blood (2006) 108 (11): 737.

https://doi.org/10.1182/blood.V108.11.737.737

Published: 2006

Journal Articles

Dasatinib (SPRYCEL®) 140 mg Once Daily (QD) vs 70 mg Twice Daily (BID) in Patients (pts) with Advanced Phase Chonic Myeloid Leukemia (ABP-CML) or Ph(+) ALL Who Are Resistant or Intolerant to Imatinib (im): Results of the CA180-035 Study.

Hagop Kantarjian, O. Ottmann, R. Pasquini, Y.T. Goh, D.W. Kim, J. VanTornout, A. Damokosh, N. Shah

Blood (2006) 108 (11): 746.

https://doi.org/10.1182/blood.V108.11.746.746

Published: 2006

Journal Articles

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Andreas Hochhaus, MD, Philipp Erben, MD, Susan Branford, PhD, Jerald Radich, MD, D.W. Kim, MD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Martin C. Mueller, MD, Jana Hoffmann, Francesca Palandri, Simona Soverini, MD, Timothy Hughes, MD, Yaping Shou, MD PhD, Aaron Weitzman, MD, Michele Baccarani, MD

Blood (2006) 108 (11): 749.

https://doi.org/10.1182/blood.V108.11.749.749

Published: 2006

Journal Articles

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

Jorge Cortes, D.W. Kim, F. Guilhot, G. Rosti, R.T. Silver, A. Gollerkeri, P. Agarwal, S. Branford, J.F. Apperley

Blood (2006) 108 (11): 2160.

https://doi.org/10.1182/blood.V108.11.2160.2160

Published: 2006

Journal Articles

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

Francois Guilhot, J.F. Apperley, N. Shah, D.W. Kim, A. Grigg, S. Cheng, M. Iyer, J. Cortes

Blood (2005) 106 (11): 39.

https://doi.org/10.1182/blood.V106.11.39.39

Published: 2005

Journal Articles

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

M. Talpaz, P. Rousselot, D.W. Kim, F. Guilhot, S. Corm, E. Bleickardt, R. Zink, G. Rosti, S. Coutre, C. Sawyers

Blood (2005) 106 (11): 40.

https://doi.org/10.1182/blood.V106.11.40.40

Published: 2005

NARROW

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

First Results from a Collaborative Initiative To Develop an International Scale for the Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors.

Dasatinib (SPRYCEL®) 140 mg Once Daily (QD) vs 70 mg Twice Daily (BID) in Patients (pts) with Advanced Phase Chonic Myeloid Leukemia (ABP-CML) or Ph(+) ALL Who Are Resistant or Intolerant to Imatinib (im): Results of the CA180-035 Study.

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

Email alerts

ASH Publications

American Society of Hematology

Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.

First Results from a Collaborative Initiative To Develop an International Scale for the Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors.

Dasatinib (SPRYCEL®) 140 mg Once Daily (QD) vs 70 mg Twice Daily (BID) in Patients (pts) with Advanced Phase Chonic Myeloid Leukemia (ABP-CML) or Ph(+) ALL Who Are Resistant or Intolerant to Imatinib (im): Results of the CA180-035 Study.

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.

A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 ‘START-A’ Study.

A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only